KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $7.1 million.

  • Supernus Pharmaceuticals' Change in Receivables rose 20063.51% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2989.29%. This contributed to the annual value of -$2.1 million for FY2024, which is 8892.62% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Change in Receivables stood at $7.1 million for Q3 2025, which was up 20063.51% from -$4.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Change in Receivables' 5-year high stood at $12.9 million during Q2 2022, with a 5-year trough of -$22.0 million in Q1 2023.
  • Its 5-year average for Change in Receivables is -$129421.1, with a median of $2.4 million in 2023.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 25652.52% in 2022, then tumbled by 47636.41% in 2023.
  • Supernus Pharmaceuticals' Change in Receivables (Quarter) stood at $3.5 million in 2021, then plummeted by 59.6% to $1.4 million in 2022, then skyrocketed by 69.74% to $2.4 million in 2023, then crashed by 239.37% to -$3.3 million in 2024, then soared by 314.08% to $7.1 million in 2025.
  • Its Change in Receivables was $7.1 million in Q3 2025, compared to -$4.8 million in Q2 2025 and $3.6 million in Q1 2025.